<DOC>
	<DOCNO>NCT00315185</DOCNO>
	<brief_summary>The purpose study determine role cetuximab ( Erbitux ) chemotherapy advance colorectal carcinoma . This study determine new agent improve one 's response standard treatment .</brief_summary>
	<brief_title>Study Paclitaxel , Carboplatin , Cetuximab Advanced Lung Cancer</brief_title>
	<detailed_description>This research study do determine cetuximab improve efficacy standard chemotherapy . This agent target epidermal growth factor receptor ( EGFR ) . EGFR sit outside tumor cell control tumor cell growth . This agent look alone chemotherapy drug non-small-cell lung cancer ( NSCLC ) . It show safe shrink tumor . There little information combination agent paclitaxel carboplatin . This study combine cetuximab monthly carboplatin weekly paclitaxel .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically cytologically document stage IIIB IV NSCLC Measurable disease ECOG performance status 01 Asymptomatic brain metastasis ; must complete radiotherapy/radiosurgery least 2 week prior enrollment steroid . Radiotherapy must complete &gt; 2 week prior enrollment patient must recover adverse event radiotherapy . &gt; /= 18 year age Adequate hematologic function : absolute neutrophil count ( ANC ) &gt; /= 1,500/mm3 ; platelet &gt; /= 100,000/mm3 . Adequate hepatic function : total bilirubin &lt; /= 1.5 X upper limit normal ( ULN ) ; AST ALT &lt; /= 2.5 X ULN . Adequate renal function : serum creatinine &lt; /= 1.5mg/dL creatinine clearance &gt; /= 50cc/minute serum creatinine &gt; 1.5 Signed approve informed consent protocol approve informed consent Health Insurance Portability Accountability Act ( HIPAA ) EGFR status immunohistochemistry ( IHC ) sufficient tissue available Women childbearing potential positive pregnancy test enrollment within 7 day treatment . In addition , men enrol study understand risk sexual partner childbearing potential practice effective method birth regulation/control . Note : Patients consider childbearing potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Patients prior malignancy , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient diseasefree 3 year . Patients significant history cardiac disease , i.e. , uncontrolled hypertension , unstable angina , uncontrolled congestive heart failure , myocardial infarction within past year , cardiomyopathy decrease ejection fraction , cardiac ventricular arrythmias within last year require new treatment . Patients uncontrolled seizure disorder , active neurological disease . Patients symptomatic brain metastasis . Patients receive prior systemic chemotherapy . Patients receive prior cetuximab therapy specifically directly target EGF pathway . Prior infusion reaction monoclonal antibody prior hypersensitivity Cremophor EL . Patients known peripheral neuropathy ( &gt; grade 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Advanced Non-small Cell Lung Cancer</keyword>
	<keyword>First Line Treatment</keyword>
</DOC>